Lv1
30 积分 2022-05-19 加入
Abstract ND11: Chemoproteomic-enabled discovery of VVD-214, a synthetic lethal allosteric inhibitor of WRN helicase
26天前
已关闭
Evaluating TRKB activity of novel preclinical brain-penetrant ROS1 and ALK inhibitors
1个月前
已关闭
HRO761, a first-in-class, clinical stage WRN inhibitor with potent preclinical anti-tumor activity in MSIhigh models
7个月前
已完结
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation
1年前
已完结
Tumor-agnostic drug development in dMMR/MSI-H solid tumors
1年前
已完结
The non-small-cell lung cancer drug market
1年前
已完结
Developing an IKZF2 glue degrader
1年前
已完结
The DNA damage response and cancer therapy
1年前
已完结
Targeting lipid–protein interaction to treat Syk-mediated acute myeloid leukemia
1年前
已完结
HH2853 is a selective small molecular dual inhibitor of EZH1/2 with potent anti-tumor activities
1年前
已关闭
皖公网安备34019202002308
